LONG MINI FUTURE - ELI LILLY & CO | Real-time Bid/Ask 10:01:00 2024-07-11 am EDT | ||
| 3.45 CHF / 3.46 CHF | -0.43% |
|
| Current month | +7.10% | ||
| 1 month | +25.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 3.47 | +3.58% |
| 24-07-09 | 3.35 | +2.13% |
| 24-07-08 | 3.28 | +2.50% |
| 24-07-05 | 3.2 | +2.56% |
| 24-07-04 | 3.12 | +1.96% |
Delayed Quote Swiss Exchange
Last update July 10, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| MLLANV | |
| ISIN | CH1290665988 |
| Date issued | 2023-10-11 |
| Strike | 554.6 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.65 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.47 CHF |
|---|---|
| Lowest since issue | 0.34 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.29% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
877.2
USD
Spread / Average Target
-6.66%
- Stock Market
- Certificates
- MLLANV Certificat
